Literature DB >> 11836578

Participation of Fas-mediated apoptotic pathway in KB, a human head and neck squamous cell carcinoma cell line, after irradiation.

Masako Uno1, Takemi Otsuki, Kenichiro Yata, Tomohiro Fujii, Haruko Sakaguchi, Takeshi Akisada, Junichi Hiratsuka, Yoshinari Imajo, Tamotsu Harada.   

Abstract

In head and neck clinical oncology, recurrent cancer after initial irradiation therapy is no longer sensitive to irradiation. To explore the irradiation resistance in head and neck squamous cell carcinoma, a human cell line, KB, derived from the floor of the oral cavity was used. The participation of the Fas-mediated apoptotic pathway was suggested by the upregulation of the surface Fas molecule, the reduction of the apoptotic cell fraction after inhibition of caspase 8 which is a Fas-related initiator caspase, and the changes in Fas-related genes after irradiation. Therefore, it is suggested that disruption of the Fas-mediated apoptotic pathway participates in the acquisition of irradiation-resistance in HNSCC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836578

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

1.  Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.

Authors:  Jie Yang; Donna McEachern; Wenyan Li; Mary A Davis; Hua Li; Meredith A Morgan; Longchuan Bai; Jonathan T Sebolt; Haiying Sun; Theodore S Lawrence; Shaomeng Wang; Yi Sun
Journal:  Mol Cancer Ther       Date:  2011-01-31       Impact factor: 6.261

2.  Molecular mechanism of acute radiation enteritis revealed using proteomics and biological signaling network analysis in rats.

Authors:  Shunxin Song; Dianke Chen; Tenghui Ma; Yanxin Luo; Zuli Yang; Daohai Wang; Xinjuan Fan; Qiyuan Qin; Beibei Ni; Xuefeng Guo; Zhenyu Xian; Ping Lan; Xinping Cao; Mingtao Li; Jianping Wang; Lei Wang
Journal:  Dig Dis Sci       Date:  2014-06-14       Impact factor: 3.199

Review 3.  Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.

Authors:  Michael R Shafique; Lary A Robinson; Scott Antonia
Journal:  Cancer Manag Res       Date:  2018-05-01       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.